ES2611464T3 - Polisacárido capsular bacteriano para su uso como vacuna o para su unión a proteínas en vacunas de conjugados - Google Patents

Polisacárido capsular bacteriano para su uso como vacuna o para su unión a proteínas en vacunas de conjugados Download PDF

Info

Publication number: ES2611464T3
Authority: ES; Spain
Prior art keywords: range; type; group; capsular polysaccharide; kav
Prior art date: 1997-12-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES10005184.6T

Other languages

English (en)

Spanish (es)

Inventor

Francis Michon

Milan Blake

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Ireland Pharmaceuticals

Original Assignee

Pfizer Ireland Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-23

Filing date

1998-12-23

Publication date

2017-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2611464(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-23 Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals

2017-05-09 Application granted granted Critical

2017-05-09 Publication of ES2611464T3 publication Critical patent/ES2611464T3/es

2018-12-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

150000004676 glycans Chemical class 0.000 title claims abstract description 146
229920001282 polysaccharide Polymers 0.000 title claims abstract description 145
239000005017 polysaccharide Substances 0.000 title claims abstract description 145
230000001580 bacterial effect Effects 0.000 title claims abstract description 36
102000004169 proteins and genes Human genes 0.000 title claims abstract description 13
108090000623 proteins and genes Proteins 0.000 title claims abstract description 11
229960005486 vaccine Drugs 0.000 title description 26
108010060123 Conjugate Vaccines Proteins 0.000 title description 9
229940031670 conjugate vaccine Drugs 0.000 title description 9
238000000034 method Methods 0.000 claims abstract description 54
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 30
239000006228 supernatant Substances 0.000 claims abstract description 22
230000001413 cellular effect Effects 0.000 claims abstract description 19
238000000926 separation method Methods 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims abstract description 13
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 12
102000039446 nucleic acids Human genes 0.000 claims abstract description 10
108020004707 nucleic acids Proteins 0.000 claims abstract description 10
150000007523 nucleic acids Chemical class 0.000 claims abstract description 10
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims abstract description 8
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims abstract description 8
230000002163 immunogen Effects 0.000 claims abstract description 8
239000003636 conditioned culture medium Substances 0.000 claims abstract description 7
238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 6
239000012535 impurity Substances 0.000 claims abstract description 6
230000008569 process Effects 0.000 claims abstract description 6
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims abstract description 4
229910000104 sodium hydride Inorganic materials 0.000 claims abstract description 3
108091005461 Nucleic proteins Proteins 0.000 claims abstract 2
108020004513 Bacterial RNA Proteins 0.000 claims description 2
238000000605 extraction Methods 0.000 abstract description 22
210000004027 cell Anatomy 0.000 description 38
239000002585 base Substances 0.000 description 20
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
241000894006 Bacteria Species 0.000 description 13
208000015181 infectious disease Diseases 0.000 description 12
230000007062 hydrolysis Effects 0.000 description 11
238000006460 hydrolysis reaction Methods 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
239000000427 antigen Substances 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000012634 fragment Substances 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
239000012228 culture supernatant Substances 0.000 description 9
238000009826 distribution Methods 0.000 description 9
238000005227 gel permeation chromatography Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
108010013639 Peptidoglycan Proteins 0.000 description 8
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
241000192125 Firmicutes Species 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
239000012141 concentrate Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
125000003047 N-acetyl group Chemical group 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000013375 chromatographic separation Methods 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000028993 immune response Effects 0.000 description 6
238000002955 isolation Methods 0.000 description 6
239000012528 membrane Substances 0.000 description 6
150000004713 phosphodiesters Chemical class 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
238000009007 Diagnostic Kit Methods 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
241000193990 Streptococcus sp. 'group B' Species 0.000 description 5
238000006640 acetylation reaction Methods 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
-1 carboxylic acids Chemical class 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000010828 elution Methods 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000000717 retained effect Effects 0.000 description 5
239000013049 sediment Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 4
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
206010061372 Streptococcal infection Diseases 0.000 description 4
239000012505 Superdex™ Substances 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
230000021736 acetylation Effects 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
210000002421 cell wall Anatomy 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000000855 fermentation Methods 0.000 description 4
230000004151 fermentation Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
238000000569 multi-angle light scattering Methods 0.000 description 4
229950006780 n-acetylglucosamine Drugs 0.000 description 4
238000005375 photometry Methods 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
230000003595 spectral effect Effects 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
241000617590 Escherichia coli K1 Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000016943 Muramidase Human genes 0.000 description 3
108010014251 Muramidase Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
241000588650 Neisseria meningitidis Species 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
244000052616 bacterial pathogen Species 0.000 description 3
238000011097 chromatography purification Methods 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
230000006196 deacetylation Effects 0.000 description 3
238000003381 deacetylation reaction Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
229960000274 lysozyme Drugs 0.000 description 3
239000004325 lysozyme Substances 0.000 description 3
235000010335 lysozyme Nutrition 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
235000020030 perry Nutrition 0.000 description 3
239000012071 phase Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
229920000768 polyamine Polymers 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000009010 Bradford assay Methods 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000011109 contamination Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
229940045808 haemophilus influenzae type b Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
230000009851 immunogenic response Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000001471 micro-filtration Methods 0.000 description 2
229940031348 multivalent vaccine Drugs 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000007017 scission Effects 0.000 description 2
208000013223 septicemia Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000005406 washing Methods 0.000 description 2
GHAXTSRJNHYMFC-SANMLTNESA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 GHAXTSRJNHYMFC-SANMLTNESA-N 0.000 description 1
YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
SMWZGZIZOHNWBH-UHFFFAOYSA-N 3-bromo-5-phenyl-1,2-oxazole Chemical compound O1N=C(Br)C=C1C1=CC=CC=C1 SMWZGZIZOHNWBH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
240000007124 Brassica oleracea Species 0.000 description 1
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010594 Congenital pneumonia Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000194033 Enterococcus Species 0.000 description 1
241000186811 Erysipelothrix Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010021531 Impetigo Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000186781 Listeria Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010058780 Meningitis neonatal Diseases 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
230000006181 N-acylation Effects 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000700159 Rattus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940037003 alum Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
229960001212 bacterial vaccine Drugs 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000013378 biophysical characterization Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
238000009413 insulation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940060155 neuac Drugs 0.000 description 1
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000007248 oxidative elimination reaction Methods 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000009984 peri-natal effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229940031937 polysaccharide vaccine Drugs 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000004237 preparative chromatography Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
229940023143 protein vaccine Drugs 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000013638 trimer Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Materials Engineering (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Peptides Or Proteins (AREA)

ES10005184.6T 1997-12-23 1998-12-23 Polisacárido capsular bacteriano para su uso como vacuna o para su unión a proteínas en vacunas de conjugados Expired - Lifetime ES2611464T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6860897P	1997-12-23	1997-12-23
US68608P		1997-12-23

Publications (1)

Publication Number	Publication Date
ES2611464T3 true ES2611464T3 (es)	2017-05-09

Family

ID=22083630

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES10005184.6T Expired - Lifetime ES2611464T3 (es)	1997-12-23	1998-12-23	Polisacárido capsular bacteriano para su uso como vacuna o para su unión a proteínas en vacunas de conjugados
ES98966468T Expired - Lifetime ES2346022T3 (es)	1997-12-23	1998-12-23	Procedimiento para la extraccion y el aislamiento de polisacaridos capsulares bacterianos para su uso como vacunas o ligandos a proteinas como vacunas de conjugados.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES98966468T Expired - Lifetime ES2346022T3 (es)	1997-12-23	1998-12-23	Procedimiento para la extraccion y el aislamiento de polisacaridos capsulares bacterianos para su uso como vacunas o ligandos a proteinas como vacunas de conjugados.

Country Status (14)

Country	Link
US (1)	US6248570B1 (2)
EP (3)	EP3118225A1 (2)
JP (2)	JP4435413B2 (2)
KR (2)	KR100757630B1 (2)
AT (1)	ATE468403T2 (2)
AU (1)	AU754256C (2)
CA (1)	CA2316975C (2)
CZ (1)	CZ302615B6 (2)
DE (1)	DE69841676D1 (2)
DK (1)	DK1051506T4 (2)
ES (2)	ES2611464T3 (2)
HU (1)	HUP0100623A3 (2)
NO (1)	NO331100B1 (2)
WO (1)	WO1999032653A1 (2)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
OA12590A (en)	2001-01-23	2006-06-08	Aventis Pasteur	Multivalent meningococcal polysaccharide-protein conjugate vaccine.
US6693188B2 (en)	2001-08-08	2004-02-17	Cargill Incorporated	N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine
US8222232B2 (en) *	2001-02-16	2012-07-17	Cargill, Incorporated	Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7923437B2 (en) *	2001-02-16	2011-04-12	Cargill, Incorporated	Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US7816514B2 (en)	2001-02-16	2010-10-19	Cargill, Incorporated	Glucosamine and method of making glucosamine from microbial biomass
US20020115639A1 (en) *	2001-02-16	2002-08-22	Weiyu Fan	Glucosamine and method of making glucosamine from microbial blomass
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
PT1777236T (pt) *	2002-03-26	2017-02-13	Glaxosmithkline Biologicals Sa	Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
AU2003257003A1 (en) *	2002-07-30	2004-02-16	Baxter Healthcare S.A.	Chimeric multivalent polysaccharide conjugate vaccines
US20060058263A1 (en) *	2002-11-01	2006-03-16	Rogers Brent D	Heat pasturized liquids containing glucosamine
US20060003965A1 (en) *	2002-11-01	2006-01-05	Fosdick Lawrence D	N-acetyl-d-glucosamine (nag) supplemented food products and beverages
ES2461350T3 (es)	2003-01-30	2014-05-19	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
MXPA05014015A (es) *	2003-06-23	2006-03-17	Baxter Int	Vacunas contra grupo y nisseria meningitidis y combinaciones meningococales del mismo.
GB0406013D0 (en) *	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
US8652334B2 (en) *	2004-08-12	2014-02-18	Lipoxen Technologies Limited	Fractionation of charged polysaccharide
GB0502096D0 (en) *	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
CA2604363C (en)	2005-04-08	2015-06-16	Wyeth	Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2011253684B8 (en) *	2005-04-08	2013-07-11	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2006283302B2 (en) *	2005-08-24	2012-11-15	Novartis Vaccines And Diagnostics Srl	Zwitterionization of capsular saccharides
GB0522303D0 (en)	2005-11-01	2005-12-07	Chiron Srl	Culture method
WO2007084856A2 (en) *	2006-01-13	2007-07-26	Baxter International Inc.	Method for purifying polysaccharides
GB0605757D0 (en) *	2006-03-22	2006-05-03	Chiron Srl	Separation of conjugated and unconjugated components
PL2004225T3 (pl)	2006-03-22	2012-09-28	Novartis Ag	Schematy immunizacji koniugatami meningokokowymi
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
US8808707B1 (en)	2006-05-08	2014-08-19	Wyeth Llc	Pneumococcal dosing regimen
EP1872791A1 (en)	2006-06-30	2008-01-02	Institut Pasteur	Use of bacterial polysaccharides for biofilm inhibition
JP2010520320A (ja)	2007-02-28	2010-06-10	リポクセンテクノロジーズリミテッド	ポリシアル酸におけるエンドトキシンの低減
ES2665002T3 (es)	2007-03-05	2018-04-24	Om Pharma	Extracto bacteriano para trastornos respiratorios y procedimiento para su preparación
PT2129693T (pt) *	2007-03-23	2017-02-14	Wyeth Llc	Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5339243B2 (ja) *	2008-04-24	2013-11-13	株式会社微生物化学研究所	ストレプトコッカス・スイス感染症予防用ワクチン
WO2011005587A1 (en) *	2009-06-24	2011-01-13	University Of Dubuque	Vaccine compositions and methods of use to protect against infectious disease
BR112013024322B1 (pt) *	2011-03-22	2020-04-22	Serum Inst India Ltd	processo para preparação de polissacarídeos
US9400250B2 (en)	2013-09-30	2016-07-26	Han Sheng Biotech Co., Ltd.	Method for analyzing mushrooms
MY186874A (en) *	2014-02-25	2021-08-26	Msd Wellcome Trust Hilleman Laboratories Pvt Ltd	A novel downstream process for purifying polysaccharides
EP2942396A1 (en)	2014-05-07	2015-11-11	Novartis AG	Polysaccharides produced by CPSC mutants
EP3034516A1 (en) *	2014-12-19	2016-06-22	Novartis AG	Purification of streptococcal capsular polysaccharide
PE20220774A1 (es)	2015-05-04	2022-05-16	Pfizer	Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
EP3551668A1 (en) *	2016-12-06	2019-10-16	GlaxoSmithKline Biologicals S.A.	Purification process for capsular polysaccharide
JP7319929B2 (ja) *	2017-05-05	2023-08-02	セラムインスティテュートオブインディアプライベートリミティド	細菌性莢膜多糖ベース調製物からの不純物の除去方法
EP3649247A4 (en) *	2017-07-05	2021-03-31	Inventprise, LLC.	PURIFICATION OF POLYSACCHARIDES FOR VACCINE PRODUCTION USING LYTIC ENZYMES, TANGENTIAL FILTRATION AND MULTIMODAL CHROMATOGRAPHY
PT3678654T (pt)	2017-09-07	2024-08-05	Merck Sharp & Dohme Llc	Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
FR3078977B1 (fr)	2018-03-16	2023-03-17	Biomerieux Sa	Procede d'extraction d'acides nucleiques
JP2023546446A (ja) *	2020-10-22	2023-11-02	ファイザー・インク	細菌多糖を精製する方法
CN117512031B (zh) *	2023-10-16	2024-06-25	江苏金迪克生物技术股份有限公司	一种肺炎球菌荚膜多糖的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3523801A (en) †	1966-01-13	1970-08-11	Kyowa Hakko Kogyo Kk	Process for the preparation of seasonings
US3577527A (en) †	1969-01-27	1971-05-04	Us Navy	Neisseria meningitidis antigen
US4258029A (en)	1979-04-23	1981-03-24	Connaught Laboratories Limited	Synthetic adjuvants for stimulation of antigenic responses
US4413057A (en)	1980-04-14	1983-11-01	Merck & Co., Inc.	Group B streptococcal capsular polysaccharides
US4356170A (en) †	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
US4644059A (en)	1982-07-06	1987-02-17	Connaught Laboratories, Inc.	Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
EP0238739B1 (en) †	1986-03-27	1992-02-05	Swiss Serum and Vaccine Institute Berne	Klebsiella capsular polysaccharide vaccine
AU586857B2 (en) *	1986-03-27	1989-07-27	Swiss Serum And Vaccine Institute Berne	Klebsiella capsular polysaccharide vaccine
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5190746A (en)	1989-05-10	1993-03-02	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Plaque inhibiting oligosaccharide
DE69019164T2 (de)	1989-12-14	1995-09-07	National Research Council Of Canada, Ottawa, Ontario	Verbessertes meningokokkale polysaccharidkonjugatvakzin.
NZ239643A (en)	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
ZA937034B (en) *	1992-09-24	1995-06-23	Brigham & Womens Hospital	Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5811102A (en) *	1995-06-07	1998-09-22	National Research Council Of Canada	Modified meningococcal polysaccharide conjugate vaccines

1998
- 1998-12-23 WO PCT/US1998/027375 patent/WO1999032653A1/en not_active Ceased
- 1998-12-23 EP EP16182410.7A patent/EP3118225A1/en not_active Withdrawn
- 1998-12-23 KR KR1020067013976A patent/KR100757630B1/ko not_active Expired - Fee Related
- 1998-12-23 DK DK98966468.5T patent/DK1051506T4/da active
- 1998-12-23 AT AT98966468T patent/ATE468403T2/de active
- 1998-12-23 EP EP98966468.5A patent/EP1051506B2/en not_active Expired - Lifetime
- 1998-12-23 AU AU23071/99A patent/AU754256C/en not_active Expired
- 1998-12-23 US US09/221,630 patent/US6248570B1/en not_active Expired - Lifetime
- 1998-12-23 JP JP2000525570A patent/JP4435413B2/ja not_active Expired - Lifetime
- 1998-12-23 KR KR1020007006995A patent/KR100641490B1/ko not_active Expired - Lifetime
- 1998-12-23 ES ES10005184.6T patent/ES2611464T3/es not_active Expired - Lifetime
- 1998-12-23 DE DE69841676T patent/DE69841676D1/de not_active Expired - Lifetime
- 1998-12-23 ES ES98966468T patent/ES2346022T3/es not_active Expired - Lifetime
- 1998-12-23 CA CA002316975A patent/CA2316975C/en not_active Expired - Lifetime
- 1998-12-23 HU HU0100623A patent/HUP0100623A3/hu unknown
- 1998-12-23 EP EP10005184.6A patent/EP2226336B1/en not_active Expired - Lifetime
- 1998-12-23 CZ CZ20002373A patent/CZ302615B6/cs not_active IP Right Cessation
2000
- 2000-06-21 NO NO20003226A patent/NO331100B1/no not_active IP Right Cessation
2009
- 2009-09-07 JP JP2009206304A patent/JP5144613B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6248570B1 (en)	2001-06-19
JP5144613B2 (ja)	2013-02-13
JP2010011862A (ja)	2010-01-21
AU754256B2 (en)	2002-11-07
CA2316975C (en)	2009-03-24
JP4435413B2 (ja)	2010-03-17
EP1051506B8 (en)	2010-09-01
KR20060086978A (ko)	2006-08-01
ATE468403T2 (de)	2010-06-15
DE69841676D1 (de)	2010-07-01
EP2226336A1 (en)	2010-09-08
AU2307199A (en)	1999-07-12
EP1051506A1 (en)	2000-11-15
JP2001526902A (ja)	2001-12-25
KR20010033494A (ko)	2001-04-25
HUP0100623A3 (en)	2003-11-28
CZ20002373A3 (cs)	2000-12-13
CZ302615B6 (cs)	2011-08-03
EP3118225A1 (en)	2017-01-18
KR100757630B1 (ko)	2007-09-10
NO20003226D0 (no)	2000-06-21
AU754256C (en)	2004-05-20
NO331100B1 (no)	2011-10-03
HUP0100623A2 (hu)	2001-06-28
KR100641490B1 (ko)	2006-10-31
HK1147506A1 (en)	2011-08-12
DK1051506T3 (da)	2010-09-13
EP2226336B1 (en)	2016-10-19
WO1999032653A1 (en)	1999-07-01
EP1051506B2 (en)	2019-08-21
EP1051506B1 (en)	2010-05-19
DK1051506T4 (da)	2019-10-21
CA2316975A1 (en)	1999-07-01
ES2346022T3 (es)	2010-10-07
WO1999032653A9 (en)	1999-10-28

Publication	Publication Date	Title
ES2611464T3 (es)	2017-05-09	Polisacárido capsular bacteriano para su uso como vacuna o para su unión a proteínas en vacunas de conjugados
WO2015144031A1 (zh)	2015-10-01	一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
Ledov et al.	2019	Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection
ES2235228T3 (es)	2005-07-01	Procedimiento de purificacion de la toxina cm 101 del grupo gbs.
AU630093B2 (en)	1992-10-22	Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
US20010051364A1 (en)	2001-12-13	Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
ES2686875T3 (es)	2018-10-22	Exopolisacárido de la bacteria Shigella sonnei, método para producirlo, vacuna y composición farmacéutica que lo contienen
JP5689064B2 (ja)	2015-03-25	精製方法
WO2004003215A1 (en)	2004-01-08	Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides
Zhong et al.	2026	Development and immunological evaluation of a Streptococcus suis serotype 2 capsular polysaccharide conjugate vaccine
HK1147506B (en)	2017-08-04	Bacterial capsular polysaccharide for use as vaccines or for linking to proteins in conjugate vaccines
RU2818894C1 (ru)	2024-05-07	Свободные от примеси с-полисахарида капсульные полисахариды streptococcus pneumoniae с остатком 2,5-ангидроманнозы на восстанавливающем конце
RU2407792C1 (ru)	2010-12-27	СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ
ES2942133T3 (es)	2023-05-30	Purificación de polisacárido capsular estreptocócico
RU2859215C2 (ru)	2026-03-31	Комбинация пневмококковых капсульных полисахаридов эпидемически значимых для Евразийского региона серотипов (варианты), включающая её поливалентная вакцина (варианты) и способ получения высокоочищенных капсульных полисахаридов бактерии Streptococcus pneumoniae
CN119700957B (zh)	2025-12-19	一种功能化阳离子聚合物及其制备方法与应用
RU2478644C2 (ru)	2013-04-10	Способ производства фармакологически приемлемой смеси веществ, содержащей низкомолекулярные компоненты пептидогликана клеточной стенки грамотрицательных бактерий и обладающей иммуностимулирующей активностью
EA049499B1 (ru)	2025-03-28	Комбинация пневмококковых капсульных полисахаридов эпидемически значимых для евразийского региона серотипов (варианты), включающая её поливалентная вакцина (варианты) и способ получения высокоочищенных капсульных полисахаридов бактерии streptococcus pneumoniae